希普酸通过抑制炎症活动和调节肠道微生物群来缓解硫酸诱导的大肠炎
Yan Yang1, Shiqin Huang1, Yangjie Liao2
1Department of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, 410013, China; Hunan Key Laboratory of Non-Resolving Inflammation and Cancer, Changsha, 410008, China.
Biochemical and biophysical research communications
|April 5, 2024
概括
酸 (HA) 通过改善肠道屏障功能和恢复有益的肠道细菌来缓解炎症性肠病 (IBD) 症状. 这项研究表明HA作为IBD患者的潜在生物疗法.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠病 (IBD) 是一种与肠道失调和代谢问题相关的慢性疾病.
- 在IBD患者中观察到降低的hippuric acid (HA) 水平.
- 目前尚不清楚HA在肠道炎症中的治疗作用.
研究的目的:
- 在大肠炎的小鼠模型中研究酸 (HA) 的治疗作用和潜在机制.
- 探索HA对肠道微生物群组成和IBD炎症途径的影响.
主要方法:
- DSS诱导的大肠炎小鼠模型.
- 用于肠道微生物群分析的元基因组测序.
- 网络药理学,PPI分析,分子对接和KEGG通路分析.
主要成果:
- 治疗HA显著减少了结肠炎和肠道屏障损伤的临床症状.
- HA降低了促炎性细胞因子水平和调节了肠道微生物群组成,增加了有益细菌.
- 网络分析确定了由HA调节的大肠炎的关键基因和途径 (RAS,NF-κB,Rap1).
结论:
- 酸 (HA) 在缓解DSS诱导的大肠炎方面显示出治疗潜力.
- HA通过恢复肠道微生物群平衡和调节关键炎症信号通路来发挥作用.
- 在炎症性肠病 (IBD) 中,HA 是新型生物治疗策略的有希望的候选者.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Drugs for Treatment of Diarrhea-Predominant IBS
166
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
166
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
404
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
404
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
162
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
162
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
443
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
443
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127


